CADL
Candel Therapeutics Inc
NASDAQ: CADL · HEALTHCARE · BIOTECHNOLOGY
$6.18
-0.32% today
Updated 2026-04-29
Market cap
$476.11M
P/E ratio
—
P/S ratio
436.42x
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$4 – $8
Volume
1.6M
Candel Therapeutics Inc (CADL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $125000.00 | $125000.00 | $125000.00 | $125000.00 | $31000.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +0.0% | +0.0% | +0.0% | -75.2% | -100.0% | — |
| Cost of revenue | $6.61M | — | $232000.00 | $987000.00 | $23.98M | $990000.00 | $845000.00 |
| Gross profit | $-6.48M | $125000.00 | $125000.00 | $125000.00 | $-23.98M | $-990000.00 | $-845000.00 |
| Gross margin | -5185.6% | 100.0% | 100.0% | 100.0% | -77354.8% | — | — |
| R&D | $6.61M | $8.75M | $15.18M | $20.79M | $24.51M | $19.31M | $30.50M |
| SG&A | $2.35M | $4.92M | $10.67M | $14.06M | $13.72M | $14.06M | $17.77M |
| Operating income | $-9.04M | $-13.81M | $-25.73M | $-34.72M | $-38.39M | $-33.37M | $-48.27M |
| Operating margin | -7229.6% | -11048.0% | -20580.8% | -27777.6% | -123841.9% | — | — |
| EBITDA | $-8.99M | $-13.72M | $-35.84M | $-16.31M | $-37.43M | $-52.10M | $-47.42M |
| EBITDA margin | -7195.2% | -10975.2% | -28671.2% | -13046.4% | -120745.2% | — | — |
| EBIT | $-9.04M | $-13.81M | $-36.07M | $-17.09M | $-38.39M | $-53.09M | $-48.27M |
| Interest expense | $1.07M | $111000.00 | $53000.00 | $1.71M | $514000.00 | $2.09M | $2.12M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.24M | $-17.68M | $-36.12M | $-18.79M | $-37.94M | $-55.18M | $-38.18M |
| Net income growth (YoY) | — | -114.6% | -104.3% | +48.0% | -101.9% | -45.4% | +30.8% |
| Profit margin | -6592.0% | -14144.0% | -28899.2% | -15035.2% | -122383.9% | — | — |